41. Giant cell arteritis Clinical trials / Disease details

Clinical trials : 131 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 125

57 trials found

diseases per page:

Showing 1 to 10 of 57 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05380453 (ClinicalTrials.gov)	September 21, 2022	22/2/2022	Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Cli ...	A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the ...	Giant Cell Arteritis	Biological: Secukinumab 300 mg, s.c.;Drug: Placebo to match Secukinumab, s.c.	Novartis Pharmaceuticals	NULL	Recruiting	50 Years	N/A	All	146	Phase 3	Germany
2	EUCTR2021-002528-18-DK (EUCTR)	22/02/2022	30/07/2021	RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insuffi ...	RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insuffi ...	Glucocorticoid-induced adrenal insufficiency MedDRA version: 20.0;Level: LLT;Classification code 100 ...	Trade Name: Hydrokortison orion Product Name: hydrokortison Product Code: H02AB09 INN or Proposed INN: h ...	Copenhagen University Hospital Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	325	Phase 4	Denmark
3	NCT04474847 (ClinicalTrials.gov)	March 15, 2021	13/7/2020	Abatacept for the Treatment of Giant Cell Arteritis	A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis ...	Giant Cell Arteritis	Drug: Abatacept;Drug: Placebo	University of Pennsylvania	NULL	Active, not recruiting	50 Years	N/A	All	78	Phase 3	United States;Canada
4	EUCTR2020-000622-26-DE (EUCTR)	22/01/2021	17/09/2020	A Proof-of-Concept Study of Guselkumab in the Treatmentof Subjects with New-Onset or Relapsing Giant ...	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Eval ...	Giant Cell Arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Product Name: Guselkumab Product Code: CNTO1959 INN or Proposed INN: Guselkumab Product Name: Guselkuma ...	Janssen-Cilag International N.V.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;France;Canada;Spain;Poland;Belgium;Israel;Germany;Italy
5	EUCTR2020-000622-26-IT (EUCTR)	18/12/2020	24/05/2021	A Proof-of-Concept Study of Guselkumab in the Treatmentof Subjects with New-Onset or Relapsing Giant ...	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Eval ...	Giant Cell Arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Product Name: Guselkumab Product Code: [CNTO1959] INN or Proposed INN: GUSELKUMAB Other descriptive nam ...	JANSSEN CILAG INTERNATIONAL NV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	France;United States;Canada;Spain;Poland;Belgium;Germany;Italy
6	NCT04633447 (ClinicalTrials.gov)	December 10, 2020	6/11/2020	A Study to Evaluate Guselkumab for the Treatmentof Participants With New-onset or Relapsing Giant Ce ...	A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Eval ...	Giant Cell Arteritis	Drug: Guselkumab;Drug: Placebo	Janssen Research & Development, LLC	NULL	Recruiting	50 Years	N/A	All	51	Phase 2	United States;Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain
7	NCT04239196 (ClinicalTrials.gov)	July 1, 2020	19/11/2019	Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	Open Label Phase II Randomized Non-comparative Study of SC Tocilizumab Associated With IV Pulse Ster ...	Giant Cell Arteritis;Optic Ischaemic Neuropathy	Drug: tocilizumab and IV steroids combination;Other: IV steroids combination alone	Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts	Roche Chugai	Not yet recruiting	50 Years	N/A	All	58	Phase 2	France
8	NCT05394909 (ClinicalTrials.gov)	February 7, 2020	20/5/2022	Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients	TreatmentOf Giant Cell Arteritis Patients With Ultra-short Glucocorticosteroids And tociliZumab: Rol ...	GCA;TOCILIZUMAB;Glucocorticoids;PET	Drug: Tocilizumab 162Mg/0.9Ml Autoinjector	Azienda Unità Sanitaria Locale Reggio Emilia	NULL	Active, not recruiting	N/A	N/A	All	20		Italy
9	NCT03892785 (ClinicalTrials.gov)	January 27, 2020	26/3/2019	MEthotrexate Versus TOcilizumab for Treatmentof GIant Cell Arteritis: a Multicenter, Randomized, Con ...	MEthotrexate Versus TOcilizumab for Treatmentof GIant Cell Arteritis: a Multicenter, Randomized, Con ...	Giant Cell Arteritis	Drug: Prednisone treatment;Drug: Tocilizumab treatment;Drug: Methotrexate treatment;Other: Questionn ...	Centre Hospitalier Universitaire Dijon	NULL	Recruiting	50 Years	N/A	All	230	Phase 3	France
10	EUCTR2018-001003-36-HR (EUCTR)	10/04/2019	17/05/2019	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;Serbia;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...

First Previous1 2 3 4 5 6Next Last